Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 9Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Mouth Neoplasms 1Lymphedema 1HIV Infections 1Fallopian Tube Neoplasms 1Eyelid Sebaceous Gland Carcinoma 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Anus Neoplasms 1

Interventions

Fluorouracil 13Cisplatin 7Radiotherapy 6Specimen Handling 5Mitomycin 5Capecitabine 5pembrolizumab 4dehydroftorafur 4Radiation 4Drug Therapy 4Cetuximab 4Radiotherapy, Intensity-Modulated 3Paclitaxel 3Nivolumab 3Magnetic Resonance Spectroscopy 3Carboplatin 3Biopsy 3tislelizumab 2durvalumab 2aldesleukin 2VGX-3100 2Platinum 2Mitozytrex 2Immune Checkpoint Inhibitors 2Fluorodeoxyglucose F18 21,2-diaminocyclohexaneplatinum II citrate 2toripalimab 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1spartalizumab 1rocakinogene sifuplasmid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anus Neoplasms × Sentinel Lymph Node Biopsy × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡